<DOC>
	<DOCNO>NCT01455142</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial test bioequivalence two formulation insulin degludec/insulin aspart ( IDegAsp ) see efficacy safety obtain formulation 1 assume identical formulation 2 .</brief_summary>
	<brief_title>A Trial Test Bioequivalence Between NN1045 NN5401 Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) 12 month long Body mass index 18.0 28.0 kg/m^2 ( inclusive ) HbA1c equal 9.5 % central laboratory analysis Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoke 5 cigarette equivalent per day ) Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>